NextPlat (NXPL) Q3 2026 earnings review
NextPlat's pharmacy contract fees grow, but its quarterly loss widens
NextPlat, which runs US pharmacies and sells satellite phones online, grew its high-margin pharmacy contract fees while its retail drug sales shrank. Total revenue fell 24% from a year ago to $10.5 million because lower reimbursement rates and fewer retail prescriptions outweighed a fourfold jump in 340B clinic contract revenue. Chief executive David Phipps highlighted a 66% smaller net loss than last year, but the loss widened from $144,000 last quarter to $748,000, missing the company's plan to reach profitability in the third quarter.
| Revenue | $10.5M -24% from a year ago; -12% from Q2 |
|---|---|
| Pharmacy contract revenue | $2.4M +300% from a year ago; +9% from Q2 |
| Consolidated gross margin | 35.0% 19.9% a year ago; 39.5% in Q2 |
| Profitability outlook | Missed Q3 target Net loss widened to $748K from $144K in Q2 |
⚖️ Verdict: 🔴 Bearish
The story got worse because sequential progress stalled and key growth milestones slipped. Compared with the second quarter, healthcare gross margin dropped 5 percentage points to 41%, new 340B clinic signings fell by half to three, and the nationwide pharmacy website launch moved again to the fourth quarter. The bright spot: NextPlat closed its acquisition of a profitable Pensacola pharmacy right after quarter-end and opened a new Jacksonville store.
The question now is whether onboarding the 14 clinics signed this year and adding the two new Florida stores can cover the ongoing decline in existing retail prescriptions. If the new clinics refer enough patients, contract fees will push NextPlat into operating profit; if per-clinic volumes stay small, retail losses will keep eating into its $11.2 million cash balance. Fourth-quarter pharmacy contract revenue and operating income will settle it.
🐂 Bull Case
Contract Pharmacy Services Quadrupled From Last Year's Low
NextPlat runs a US pharmacy business and a UK online store for satellite phones and trackers. In healthcare, the company is shifting toward 340B contract services, where it manages discounted drugs for clinics serving low-income patients, and medication fulfillment for healthcare facilities.
Pharmacy contract revenue reached $2.4 million, up from $0.6 million a year ago and $2.2 million last quarter. Prescription volumes under 340B contracts grew 72% from a year ago. Existing 340B clinic customers added $1.0 million of the year-over-year revenue gain, new clinics added $0.6 million, and fulfillment contracts added $0.2 million.
Because contract fees carry almost no direct product cost, this revenue flows nearly dollar-for-dollar into gross profit and lifted consolidated gross margin by 15.2 percentage points from a year ago. What to watch: fourth-quarter pharmacy contract revenue, when the six clinics signed in the second quarter finish onboarding. A sequential step-up will show whether new signings are converting into meaningful fees.
New Florida Pharmacies Open a Local Services Hub
NextPlat is expanding its PharmcoRx brick-and-mortar pharmacy network across Florida to sell high-margin healthcare services to regional doctors and patients. The company completed the acquisition of Scott's Pharmacy near Pensacola "immediately after the close of the quarter" and opened a new pharmacy in Jacksonville last month.
Management said Scott's Pharmacy is profitable and already seeing better gross margins before launching new regional provider services. Because the deal closed after September 30, the third quarter included none of its sales. What to watch: fourth-quarter retail prescription volume and cash outflow in the full quarterly filing, which will show how much revenue the two stores add.
Satellite Airtime and Decathlon Lift Online Sales
Through its UK subsidiary Global Telesat Communications, NextPlat sells satellite phones, trackers and recurring network airtime plans online. Third-quarter e-commerce revenue rose 3% from a year ago to $3.8 million, though it dipped 7.3% from the second quarter's $4.1 million.
The company credited "record high-margin, recurring airtime contract revenue" and sales to customers across more than 115 countries. During the quarter, NextPlat also began selling satellite hardware through sporting-goods retailer Decathlon in 20 countries, though the release gave no update on military sales after reporting $1.75 million in the first half. What to watch: fourth-quarter e-commerce gross margin, which stayed at 24% this quarter.
🐻 Bear Case
Shrinking Retail Prescriptions Dragged Margins Down From Q2
Chief executive David Phipps said NextPlat is refocusing on "high-value, high-margin services designed to deliver consistent bottom-line results". Last quarter, finance chief Amanda Ferrio went further and targeted bottom-line profitability starting in the third quarter.
Instead, the company's loss widened from the second quarter as retail pharmacy sales fell. NextPlat blamed "lower reimbursement rates along with lower retail prescription volumes" for cutting prescription revenue by more than half from a year ago.
- Retail prescription revenue: $4.3 million, down 54.7% from a year ago and down 23.2% from last quarter
- Healthcare gross margin: 41%, up 23 percentage points from a year ago but down 5 points from last quarter's 46%
- Consolidated cost of revenue: 65.0% of sales, down 15.2 points from a year ago but up 4.5 points from last quarter
- Net loss: $748,000, narrower than last year's $2.2 million loss but five times last quarter's $144,000 loss
Lower revenue also hurt operating expense ratios: compared with a year ago, selling, general and administrative costs rose 5.5 percentage points of revenue to 19.4%, and payroll rose 3.0 points to 22.4%. What to watch: fourth-quarter operating loss, which tests whether the Pensacola store and new clinic contracts can finally push the business to breakeven.
New 340B Clinic Signings Halved and Website Slipped
NextPlat's healthcare growth relies on signing new 340B clinics—which take about 90 days to onboard before referring prescriptions—and launching a nationwide pharmacy website to sell outside Florida.
Both growth drivers slowed this quarter. NextPlat signed three new 340B contracts, down from six in the second quarter and five in the first quarter, and said those three are "expected to contribute to increased revenue in early 2027". Meanwhile, the nationwide medication fulfillment website—originally promised by June and then for the third quarter—slipped again, with the company now "on track to launch its new nationwide medication fulfillment website during the fourth quarter".
Because the five clinics signed in the first quarter only lifted sequential contract revenue by $0.2 million this quarter, each new clinic appears small. What to watch: whether the nationwide website goes live before year-end and how many 340B contracts NextPlat signs in the fourth quarter.
Risks this quarter didn't answer
Five standing risks from prior quarters received no new numbers in the third-quarter press release and depend on the upcoming quarterly filing or conference call.
- 340B client concentration: how much of the $2.4 million contract stream comes from top clinics, which the quarterly filing's concentration footnote will test.
- Medicare drug-pricing tailwind: how much of the 41% healthcare gross margin came from the January 2026 Medicare pricing rules versus contract mix, a split management has not quantified.
- Weisberg merger lawsuit: no update in the release on the class-action suit where $1.75 million was previously accrued; the filing's legal footnote will show its status.
- China online stores: no mention of the Tmall store or pet-health approvals that were due earlier this year.
- Share dilution: weighted average shares rose 4.0% from a year ago to 2.70 million, and the filing will show whether NextPlat used its $3.8 million stock-sale facility.
💲 Other KPIs
Cash fell 6.0% from last quarter's $11.9 million and is down from $13.7 million at the end of 2025. Working capital—current assets minus current liabilities—slipped to $13.5 million from $14.2 million in June, before paying for the Scott's Pharmacy acquisition after quarter-end.
Net receivables—money owed by customers and pharmacy benefit managers—fell 13.9% from June's $8.2 million peak, though they remain 19.5% above year-end 2025. Inventory rose 5.0% from last quarter to $4.3 million, up 25.5% since December despite lower overall sales.
Total debt from notes payable decreased 7.2% from $1.0 million in June and is down from $1.29 million at the end of 2025, by our math combining $122,000 of current notes and $810,000 of long-term notes. The group ended September with no material unsecured debt.
🔮 Guidance
New. NextPlat expects retail prescription volume to show "increases starting in the fourth quarter" after falling throughout the first nine months of 2026. The rebound relies on adding sales from the newly acquired Scott's Pharmacy near Pensacola and the new store in Jacksonville.
Unchanged on onboarding pace, though new signings slowed. The three 340B clinic contracts signed in the third quarter are "expected to contribute to increased revenue in early 2027" as they finish onboarding. Prior cohorts signed in the first half helped lift quarterly contract revenue from $1.9 million in the first quarter to $2.4 million in the third.
❓ Key Questions
How much revenue did the Q1 340B cohort add?
Pharmacy contract revenue rose by $200,000 from the second quarter even as the five clinics signed in the first quarter were due to start referring prescriptions. Investors need to know the typical annual revenue per onboarded clinic.
Why did retail prescription revenue drop 23% from Q2?
Prescription sales fell from $5.6 million in the second quarter to $4.3 million in the third, dragging healthcare gross margin down 5 percentage points. Management did not split the drop between lower drug reimbursement rates and lost prescription volume.
What revenue and profit does Scott's Pharmacy bring?
NextPlat closed the Pensacola pharmacy acquisition right after quarter-end and called it profitable, but did not disclose its historical sales, earnings or final cash purchase price in the release.
Why did the nationwide pharmacy website slip to Q4?
Management originally promised the 50-state medication fulfillment website before the end of June, then moved it to the third quarter, and now targets the fourth quarter for "optimization of the platform to support e-commerce at scale".